Crossmark

Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis

Published Online: 2021-08-25

Published Print: 2022-01

Authors

Boschitsch, Ewald https://orcid.org/0000-0002-9322-8826
Naegele, Oliver

Klinger, Anita

Brix-Samoylenko, Harald
License Information

Text and Data Mining valid from 2021-08-25

Version of Record valid from 2021-08-25
More Information

Article History

Received: 16 March 2021

Accepted: 16 August 2021

First Online: 25 August 2021

Declarations

:

: Ewald Boschitsch has served as a speaker and consultant for Amgen Inc.; Oliver Naegele, Anita Klinger and Harald Brix-Samoylenko declare that they have no conflicts of interest.

Document is current